News related to Flarex (Fluorometholone Ophthalmic) and/or conditions it is approved for
Bacterial Conjunctivitis Drug Besivance Approved
Source: MedicineNet Pink Eye Specialty [2009.06.01]
Title: Bacterial Conjunctivitis Drug Besivance Approved
Category: Health News
Created: 6/1/2009
Last Editorial Review: 6/1/2009
Pink Eye Pictures Slideshow: Pink Eye (Conjunctivitis)
Source: MedicineNet Eye Allergy Specialty [2008.06.27]
Title: Pink Eye Pictures Slideshow: Pink Eye (Conjunctivitis)
Category: Slideshows
Created: 6/26/2008
Last Editorial Review: 6/27/2008
What Is Dry Eye Syndrome? What Causes Dry Eye Syndrome?
Source: Eye Health / Blindness News From Medical News Today [2009.11.12]
Dry eye syndrome, also known as keratoconjunctivitis sicca (KCS), keratitis sicca, sicca syndrome, xerophthalmia, or simply dry eyes, is an eye disease in which tear film evaporation is high or tear production is low. Dry eye syndrome is commonly found in humans and some animals. The patient's eyes dry out and become inflamed.
ACAAI: Ultrashort Ragweed Therapy Boosts IgG Levels (CME/CE)
Source: MedPage Today Allergy & Immunology [2009.11.11]
MIAMI BEACH (MedPage Today) -- An ultrashort course of subcutaneous immunotherapy increased ragweed-specific IgG levels in patients with seasonal ragweed rhinoconjunctivitis, researchers said here.
Treatment Of Allergic Rhinitis Improves Coexisting Diseases
Source: Allergy News From Medical News Today [2009.11.09]
The treatment of allergic rhinitis is shown to improve co-existing conditions including conjunctivitis, asthma, sinusitis, otitis media with effusion (fluid in the middle ear) and sleep disorders according to an international expert at the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Miami Beach, Fla.
Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint In A Study Of Adult Subjects With A History Of Grass Pollen Allergies
Source: Allergy News From Medical News Today [2009.11.03]
Schering-Plough Corporation (NYSE: SGP) announced that its investigational sublingual Grass (Phleum Pratense) Allergy Immunotherapy Tablet (AIT) has met the primary endpoint in a Phase III study of adult subjects in the U.S. with a history of grass pollen induced rhinoconjunctivitis with or without asthma.
ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data At The American College Of Clinical Pharmacy (ACCP) 2009 Annual Meeting
Source: Allergy News From Medical News Today [2009.10.22]
ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA) announced poster presentations of results from the Company's Bepreve(TM) (bepotastine besilate ophthalmic solution) 1.5% Phase 3 clinical studies in allergic conjunctivitis. The studies demonstrated Bepreve was safe and well-tolerated when given twice daily for six weeks in a healthy pediatric population as young as three years of age.
|
